NASDAQ:NUVA - NuVasive Stock Price, Forecast & News

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings results on Wednesday, October, 30th. The medical device company reported $0.59 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.53 by $0.06. The medical device company had revenue of $290.80 million for the quarter, compared to analyst estimates of $283.75 million. NuVasive had a return on equity of 14.93% and a net margin of 4.15%. The company's quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.56 EPS. View NuVasive's Earnings History.

NuVasive is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for NuVasive.

NuVasive issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $310-310 million, compared to the consensus revenue estimate of $304.32 million.

17 analysts have issued 12 month price objectives for NuVasive's shares. Their forecasts range from $55.00 to $93.00. On average, they anticipate NuVasive's stock price to reach $76.63 in the next twelve months. This suggests that the stock has a possible downside of 1.6%. View Analyst Price Targets for NuVasive.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 7 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NuVasive.

News coverage about NUVA stock has been trending somewhat positive recently, InfoTrie reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. NuVasive earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the medical device company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for NuVasive.

NuVasive saw a increase in short interest in December. As of December 13th, there was short interest totalling 4,100,000 shares, an increase of 7.0% from the November 28th total of 3,830,000 shares. Based on an average trading volume of 509,600 shares, the days-to-cover ratio is currently 8.0 days. Currently, 7.9% of the shares of the stock are sold short. View NuVasive's Current Options Chain.

Some companies that are related to NuVasive include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include Incyte (INCY), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Medivation (MDVN), Starbucks (SBUX), Alibaba Group (BABA), Intel (INTC), Global Sources Ltd. (Bermuda) (GSOL), Celgene (CELG) and Skyworks Solutions (SWKS).

NuVasive's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Copper Rock Capital Partners LLC (0.56%), Janney Montgomery Scott LLC (0.10%), State of Alaska Department of Revenue (0.02%), 6 Meridian (0.02%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Carroll Financial Associates Inc. (0.01%). Company insiders that own NuVasive stock include Gregory T Lucier, Matthew Link and Paul Mcclintock. View Institutional Ownership Trends for NuVasive.

NUVA stock was sold by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC, Nisa Investment Advisors LLC, Diversified Trust Co and State of Alaska Department of Revenue. Company insiders that have sold NuVasive company stock in the last year include Gregory T Lucier, Matthew Link and Paul Mcclintock. View Insider Buying and Selling for NuVasive.

NUVA stock was purchased by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Carroll Financial Associates Inc., Zurcher Kantonalbank Zurich Cantonalbank and 6 Meridian. View Insider Buying and Selling for NuVasive.

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NUVA stock can currently be purchased for approximately $77.88.

NuVasive has a market capitalization of $4.05 billion and generates $1.10 billion in revenue each year. The medical device company earns $12.47 million in net income (profit) each year or $2.23 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.View Additional Information About NuVasive.

The official website for NuVasive is http://www.nuvasive.com/.

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]